Preview

Остеопороз и остеопатии

Расширенный поиск

Ибандронат (Бонвива) - новые возможности в лечении остеонороза: повышение приверженности к терапии - оптимизация исходов лечения

https://doi.org/10.14341/osteo2006323-30

Полный текст:

Список литературы

1. Евстигнеева Л.П., Лесняк О.М., Пивень А.И. Эпидемиология остеопоротических переломов позвоночника по данным рентгено- морфометрического анализа среди популяциионной выборки жителей г. Екатеринбурга 50 лет и старше. // Остеопороз и остеопатии, 2001; №2:2-6

2. Ершова О.Б., Семенова О.В., Дегтярев А.А. Результаты проспективного изучения исходов переломов проксимального отдела бедра. // Остеопороз и остеопатии, 2000; № 1: 9-10.

3. Лесняк О.М. Фармакоэкономика средств профилактики и лечения остеопороза. // В кн. «Руководство по остеопорозу», Москва, «Бином» 2003: 469--481.

4. Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. и др. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия (по данным многоцентрового исследования). // Остеопороз и остеопатии, 2002; № 1: 8-11.

5. Bartl R., Goette S., Hadji P., Hammerschmidt Т.: Persistence and compliance with daily- and weekly-administered bisphosphonates in German women with osteoporosis ECCEO, 2005 Poster (P I95)

6. Baus F., Lalla S., Endele R., Hothorn L.H.: The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. // J. Rheumatology, 2002, Vol. 29, pp. 2200-2208

7. Baus F., Wagner M., Hothorn L.H.: Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. // J. Rheumatology, 2002b, Vol. 29, pp. 990-998

8. Bauss F., Russell R.G.G.: Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. // Osteoporosis International, 2003, Vol. 15, pp. 423-433

9. Black D.M., Cummings S.R., Karpf D.B., et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group // Lancet, 1996, Vol. 348, pp. 1535-1541 5.

10. Body J.J., Diel I.J., Lichinister M.R., et al.: Ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasis (MF4265 Study Group). // Annual Oncology, 2003, Vol. 14, pp. 1399-1405

11. Body J.J.: Dosing regimens and main adverse events of bisphosphonates. // Seminars in Oncology, 2001, Vol. 28, (suppl 11), pp. 49-53

12. Bone H.G., Adami S., Rizzoli R., Favus M., Ross P.D., Santora A., Prahalada S., Daifotis A., Orloff J., Yates J.: Weekly administration of

13. Boonen S., Haentjens P., Vandenput L., Vanderschueren D.: Pre venting osteoporotic fractures with antiresorptive therapy: implications on microarchitectural changes. // J Internal Medicine, 2004, Vol. 255, pp. 1-12

14. Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., Li Z., Balske A., Lindsay R.: The efficacy and tolerability of risedronate once a week for the treatment of postmeno pausal osteoporosis. // Calcified Tissue International, 2002, Vol. 71, pp. 103-111

15. Brumsen C., Papapoulos S.E., Lips P., Geelhoed-Duijvestijn P.H., Hamdy N.A., Landman J.O., McCloskey E.V., Netelenbos J.C., Pauwels E.K., Roos J.C., Valentijn R.M., Zwinderman A.H.: Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-con trolled clinical trial with a 2-year open extension. // J. Bone Mineral Research, 2002, Vol. 17, pp. 1057-1064

16. Campion G., Melton L.J.: Hip fractures in the elderly: a worldwide projection., Osteoporosis International, 1992, Vol. 2, pp. 285-289

17. Chaiamnuay S., Saag K.G.: Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates. Reviews En docrine Metabolic Disorders, 2006 (Epub ahead of print)

18. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gilbride J., Schimmer R.S., Delmas P.D.: Effects of Oral Ibandronate Administered Daily or Intermittenly on Fracture risk in postmenopausal osteoporosis. // J. Bone and Mineral Research, 2004, Vol. 19, pp. 1241-1249-1

19. Cooper A., Drake J., Brankin E. on behalf of the persistent in vestigators: Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate results from the PERSIST study. // International J Clinical Practice, 2006, Vol. 60, pp. 896-905

20. Cooper C., Atkinson E.J., Jacobsen S.J., O'Fallon M., Melton L.J.: Population-based study of survival after osteoporotic fractures. // American J. Epidemiology, 1993, Vol. 137, pp. 1001-1005

21. Cooper C., Emkey R.D., McDonald R.H., Hawker G., Bianchi G., Wilson K., Schimmer R.C.: Efficacy and safety of oral weekly ibandro nate in the treatment of postmenopausal osteoporosis. // J. Clinical Endo crinology Metabolism, 2003, Vol. 88, pp. 4609-4615

22. Cramer J.A., Silverman S.: Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. // American J. Medicine, 2006, Vol. 119, (suppl 1) S12-17

23. Gumming R.G., Nevitt M.C., Cummings S.R.: Epidemiology of hip fractures. // J. Epidemiology Review, 1997, Vol. 19, pp. 244-257

24. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner Т.А., Palermo L., Prineas R., Rubin S.M., Scott J.C.,

25. Vogt T., Wallace R., Yates A.J., LaCroix A.Z.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral frac tures: results from the Fracture Intervention Trial. // J American Medical Association, 1998, Vol. 280 (24), pp. 2077-2082 6

26. Delmas P., Recker R., Stakkestad J.A., et al.: Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administrated daily or with a unique drug-free interval: results from a pivotal phase HI study (abstract) // Osteoporosis International, 2002, Vol. 13, (suppl 1), S15.

27. Eastell R., Reid D.M., Comston J., Cooper C., Fogelman I., Francis R.M., Hay S.M., Hosking D.J., Purdie D.W., Ralston S.H., Reeve J., RussellR.G., Stevenson J.C.: Secondary prevention of osteoporosis when should a non-vertebral fracture be a trigger for action? // Monthly J Association Physicians, 2001, Vol. 94, pp. 575-597

28. Emkey M., Lewiecki E.M., Burdeska A., Mairon N., Rowell L., Eisman J.A.: Two-year efficacy and tolerability of intermittent intrave nous ibandronate injections in postmenopausal osteoporosis: the DIVA study, 2005 3

29. Emkey R., Koltun W., Beusterien K., Seidman L., Kivitz A., Devas V., Masanauskaite D.: Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). // Current Medical Research Opinion, 2005, Vol. 21, pp. 1895-1903

30. Emkey R.D., Ettinger M.: Improving compliance and persistence with bisphosphonate therapy for osteoporosis. // American J Medicine, 2006, Vol. 119 (suppl 1): S18-24

31. Emkey R.D., Ettinger M.: Improving compliance and persistence with bisphosphonate therapy for osteoporosis. // American J Medicine, 2006 Vol. 21, pp. 1453-1460

32. Fleisch H.: The bisphosphonate ibandronate given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. // Osteoporosis International, 1996, Vol. 6, pp. 166-170

33. Frost H.M.: Tetracycline based histological analysis of bone remodeling. // J. Calcified Tissue Research, 1969, Vol. 3, pp.211-237

34. Gamero P., Hausher E., Chapuy M.C., et.al.: Markers of bone resorption predict hip fracture in elderly women: the Epidos prospective study. J. Bone Mineral Research, 1996, Vol. 11, pp. 1531-1538

35. Garnero P., Dargent-Molina P., Hans D., Schott A.M., Breart G., Meunier P.J., Delmas P.D. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the predic tion of hip fracture in elderly women? The EPIDOS prospective study. J. Osteoporosis International, 1998, Vol. 8, pp. 563-569

36. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D.: Bio chemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone Min eral Research, 2000 Vol. 15, pp. 1526-1536

37. Hamilton B., McCoy K., Taggert H.: Tolerability and compliance with residronate in clinical practice. // Osteoporosis International, 2003, Vol. 14, pp. 259-262

38. Harris S.T., Watts N.B., Genant H.K., et al.: Effects of risedro nate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. // J American Medical Association, 1999, Vol. 282 (14): 1344-1352 8

39. Herrmann Z., Schoeter К.Н.: The new bisphosphonate ibandro nate in the treatment of tumor-induced hypercalcemia. // Oncology, 1999, Vol. 22, pp. 208-211

40. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D.: Changes in bone density and turnover explain the reduc tions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. // J. Clinical Endocrinology Metabolism, 2002, Vol. 87, pp. 1586-1592

41. Johnel O.: The socioeconomic burden of fractures: today and in the 21st century. // American J Medicine, 1997, Vol. 103, 20S-26S

42. Karam S.M.: Lineage commitment and maturation of epithelial cells in the gut. // Frontiers Bioscience, 1999, Vol. 4, D286-D298

43. Lalla S., Hothorn L.A., Haag N., Bader R., Bauss F.: Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. // J. Osteoporosis International, 1998, Vol. 8, pp. 97-103 28. 28 № 2/2006 Остеопороз и остеопатии ОБЗОРЫ

44. Leu С., Rodan G.A., Reszka A.A.: Relative binding affinities of bisphosphonates for human bone (abstract). // J. Bone Mineral Research, 2003, Vol. 18, (suppl 2) S374

45. Liberman U.A., Weiss S.R., Broil J., et al.: Effect of oral alen dronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. // New England J Medicine, 1995, Vol. 333 (22), pp. 1437-1443 4

46. McClung M.R., Geusens P., Miller P.D., et al.: Effect of risedronate on risk of hip fracture in elderly women. Hip Intervention Program Study Group. // New England J Medicine, 2001, Vol. 344, pp. 333-340 10

47. Monier-Faugere M.C., Friedler R.M., Bauss F., Malluche H.H.: A new bisphosphonate, BM 21.0955 prevents bone loss associated with cessation of ovarian function in experimental dogs. // J. Bone Mineral Research, 1993, Vol. 8, pp. 1345-1355

48. Monier-Faugere M.C., Geng Z., Paschalis E.P., Qi Q., Arnala I., Bauss F., Boskey A.L., Malluche H.H.: Intermittent and continuous admin istration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. // J. Bone Mineral Research, 1999, Vol. 14, pp. 1768-1778

49. Muller R., Hannan M.K., Smith S.Y., Bauss F. Intermittent iban dronate preserves bone quality and bone strength and quality in ovari ectomized cynomolgus monkeys. // J. Bone Mineral Research, 2006 (in press)

50. Peter C.P., Handt L.K., Smith S.M.: Esophageal irritation due to alendronate sodium tablets: possible mechanisms. // Digestive Disease Sciences, 1998, Vol. 43, pp. 1998-2002

51. Pols H.A., Felsenberg D., Hanley D.A., et al.: Multinational, pla cebo-controlled randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. // Osteoporosis International, 1999, Vol. 9, pp. 461-468 7

52. Ralston S.H., Thiebaud D., Herrmann Z., et al.: Dose-response study of ibandronate in the treatment of cancer-associated hypercalce mia. // British J Cancer, 1997, Vol. 75, pp. 295-300

53. Recker R.R., Gallagher R., Amonkar M., Smith J.C., MacCosbe P.E.: Medication persistence is better with weekly bisphosphonates, but it remains suboptimal (abstract SA407). J Bone Mineral Research, 2004, Vol. 19(Suppl l). S172

54. Recker R.R., Weinsten R.S., Chesnut C.H., Schimmer R.C., Mahoney P., Hughes C., Bonvoisin B., Meunier P.J.: Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. // Osteoporosis International, 2004, Vol. 15, pp. 231-237

55. Reginster J., Felsenberg D., Cooper C., Stakkestad J.A., Miller P.D., Kendler D.L., Adami S., McClung M.R., Bolognese M.A., Civitelli R.,Dumont E., Bonvoisin B., Recker R.R., Delmas P.D.: A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. // Osteoporosis International, 2006, Vol. 17, pp. 159-166

56. Reginster J., Minne H.W., Sorensen O.H., et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. // Osteoporosis International, 2000 Vol. 11, pp. 83-91 9

57. Reginster J.Y., Adami S., Lakatos P., et al.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2- year results from the MOBILE study. // J. Annals Rheumatic Disease, 2006, Vol. 65, pp. 654-661 2

58. Reginster J.Y., Christiansen C., Roux C., Fechtenbaum J., Rouillon A., Tou K.P.: Intermittent cyclic tiludronate in the treatment of osteoporosis. // Osteoporosis International, 2001, Vol. 12, pp. 169-177

59. Reid I.R., Brown J.P., Burckhardt P., et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. // New England J Medicine, 2002, Vol. 346, pp. 653-661

60. Rizzoli R., Greenspan S.L., Bone G., Schnitzer T.J., for the Alendronate once-weekly study group: Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. // J Bone Mineral Research, 2002, Vol. 17, pp. 1988- 1996

61. Rosen C.J.: Postmenopausal osteoporosis. // New England J Medicine, 2005, Vol. 353, pp. 595-603

62. Ryan P.J., Blake G.M., Davie M., Haddaway M., Gibson T., Fogelman I.: Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. // Osteoporosis International, 2000, Vol. 11, pp. 171-176

63. Sambrook P., Olszynski W.P., Leigh C., Masanauskaite D., Bon voisin B., Emkey R.: Similar safety profile of intravenous ibandronate injection and daily oral ibandronate in postmenopausal osteoporosis: the DIVA study. // Arthritis Rheumaism, 2005, Vol. 52 (suppl 9), S296

64. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., Felsenberg D., Recker R.R., Tonino R.P., Roux C., Pinchera A., Foldes A.J., Greenspan S.L., Levine M.A., Emkey R., Santora A.C., Kaur A.., Thompson D.E., Yates J., Orloff J.J.: Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10 mg daily in the treatment of osteopo rosis. Alendronate Once-Weekly Study Group. // Aging (Milano), 2000, Vol. 12, pp. 1-12

65. Sernbo I., Johnell O.: Consequences of a hip fracture: a prospective study over a 1 year. // Osteoporosis International, 1993, Vol. 3, pp. 148-153; Beatriz J.E., Perry H.M.: Age-related osteoporosis, Clinical Geriatric Medicine, 1994, Vol. 10, pp. 575-577

66. Smith S.Y., Recker R.R., Hannan M., Muller R., Bauss E.: Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. // J. Bone, 2003, Vol. 32, pp. 45-55

67. Tosteoson A.N., Grove M.R., Hammond C.S., Moncur M.M., Ray G.T., Hebert G.M., Pressman A.R., Ettinger В.: Early discontinuation of treatment for osteoporosis. // American J. Medicine, 2003, Vol. 115, pp. 209-216

68. Tripathy D., Budde M., Bergstorm В.: Oral daily ibandronate: an effective and convenient therapy for the reduction of skeletal complications in breast cancer patients with bone metastases (Bondronat MF4434 Study Group). // Annual Oncology, 2002, Vol. 13 (suppl 5) p. 168 (Abstact)

69. Wasnich R.D., Miller P.D.: Antifracture efficacy of antiresorptive agents are related to changes in bone density. // J. Clinical Endocrinology Metabolism, 2000, Vol. 85, pp. 231-236

70. Watts N.B., Harris S.T., Genant H.K., et al.: Intermitten cyclical etidronate treatment of postmenopausal osteoporosis. // New England J Medicine, 1990, Vol. 323, pp. 73-79

71. Weel A.E.A.M., Seibel M.J., Hofman A., et.al.: Which fractures are associated with high bone resorption in elderly women? The Rotterdam study. J. Bone Mineral Research, 1999, Vol. 14, S160 World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series, 1994, № 843, WHO, Geneva World Health Organization Guidelines for the preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva

72. Клинические рекомендации Остеопороз: диагностика, профилактика и лечение (под редакцией проф. Л.И. Беневоленской и проф. О.М. Лесняк). Геотар-Медиа, Москва. 2005: 171стр.


Рецензия

Для цитирования:


., ., . Ибандронат (Бонвива) - новые возможности в лечении остеонороза: повышение приверженности к терапии - оптимизация исходов лечения. Остеопороз и остеопатии. 2006;9(3):23-30. https://doi.org/10.14341/osteo2006323-30

For citation:


Belaya Z.E., Rozhinskaya L.Y., Mel'nichenko G.A. Ibandronat (Bonviva) - novye vozmozhnosti v lechenii osteonoroza: povyshenie priverzhennosti k terapii - optimizatsiya iskhodov lecheniya. Osteoporosis and Bone Diseases. 2006;9(3):23-30. (In Russ.) https://doi.org/10.14341/osteo2006323-30

Просмотров: 475


ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)